Company Growth (employees)
Regeneron Pharmaceuticals was founded in 1988 and is headquartered in Tarrytown, US
Regeneron Pharmaceuticals Office Locations
Regeneron Pharmaceuticals has offices in Tarrytown, Rensselaer, Bernards, Limerick and in 1 other location
Tarrytown, US (HQ)
777 Old Saw Mill River Rd
Dublin, IE
Harcourt Centre Harcourt St
Bernards, US
110 Allen Rd
Rensselaer, US
81 Columbia Turnpike
Regeneron Pharmaceuticals Financials and Metrics
Regeneron Pharmaceuticals Financials
Regeneron Pharmaceuticals's revenue was reported to be $1.3 b in Q1, 2017
USD
Revenue (Q1, 2017) | 1.3 b |
Gross profit (Q1, 2017) | 1.3 b |
Gross profit margin (Q1, 2017), % | 95% |
Net income (Q1, 2017) | 248.9 m |
EBIT (Q1, 2017) | 430.5 m |
Market capitalization (12-Oct-2017) | 51.9 b |
Cash (31-Mar-2017) | 811.8 m |
Regeneron Pharmaceuticals's current market capitalization is $51.9 b.
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 2.1 b | 2.8 b | 4.1 b | 4.9 b |
Revenue growth, % | 34% | 46% | 18% | |
Cost of goods sold | 118 m | 129 m | 241.7 m | 194.6 m |
Gross profit | 2 b | 2.7 b | 3.9 b | 4.7 b |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 665.7 m | 725.8 m | 869.6 m | 998.6 m | 1.1 b | 1.2 b | 1.2 b | 1.2 b | 1.3 b |
Cost of goods sold | 29.9 m | 33.7 m | 42.6 m | 60.9 m | 67.2 m | 78.9 m | 41.2 m | 29.9 m | 61.3 m |
Gross profit | 635.8 m | 692.1 m | 827 m | 937.8 m | 1.1 b | 1.1 b | 1.2 b | 1.2 b | 1.3 b |
Gross profit Margin, % | 96% | 95% | 95% | 94% | 94% | 93% | 97% | 98% | 95% |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 535.6 m | 648.7 m | 809.1 m | 535.2 m |
Inventories | 70.4 m | 128.9 m | 238.6 m | 399.4 m |
Current Assets | 1.8 b | 2.2 b | 2.9 b | 3.2 b |
PP&E | 2.1 b |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 600.1 m | 646.6 m | 507.9 m | 390.6 m | 654.6 m | 604.2 m | 646.5 m | 920.4 m | 811.8 m |
Inventories | 109.9 m | 120.3 m | 133.9 m | 171.3 m | 190.7 m | 303.3 m | 316.1 m | 345.6 m | 466.6 m |
Current Assets | 1.9 b | 2.2 b | 2.3 b | 2.3 b | 2.7 b | 3.1 b | 3.2 b | 3.5 b | 3.7 b |
PP&E | 1.7 b | 1.8 b | 1.9 b | 2.3 b |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 424.4 m | 348.1 m | 636.1 m | 895.5 m |
Depreciation and Amortization | 41.2 m | 52.7 m | 74.9 m | 104.7 m |
Inventories | (48 m) | (61 m) | (110 m) | (149.8 m) |
Cash From Operating Activities | 583.6 m | 743.2 m | 1.3 b | 1.5 b |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 158.2 m | 237.9 m | 76 m | 270.7 m | 481.1 m | 165.7 m | 377.6 m | 642.4 m | 248.9 m |
Depreciation and Amortization | 24.5 m | 38.6 m | 16 m | 31.3 m | 52 m | 23 m | 48 m | 75.8 m | 38.1 m |
Inventories | (37.3 m) | (50.9 m) | (5.9 m) | (49.9 m) | (81.5 m) | (62.3 m) | (72.9 m) | (99.7 m) | (69.7 m) |
Cash From Operating Activities | 381.3 m | 544.9 m | (87.5 m) | 156.1 m | 1 b | 29.3 m | 444.5 m | 1.1 b | 355.9 m |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 244.3 k |
Financial Leverage | 1.6 x |
Regeneron Pharmaceuticals Market Value History
Regeneron Pharmaceuticals Median Salaries
Source: 186 public H-1B filings from Regeneron Pharmaceuticals
